Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Diagnostics & Research

Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing and sterile fill-finish services. It also provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.

Revenue projections:

Revenue projections for SYNGENE
Revenue projections for SYNGENE

Syngene International Limited's revenues are expected to fall below last year's, and this forecast tends to raise concerns among investors. A revenue drop can negatively impact the company's profitability, making investors more cautious about their positions due to the risks of declining financial performance.

Financial Ratios:

currentRatio 1.38000
forwardPE 35.98421
debtToEquity 9.47300
earningsGrowth -0.19500
revenueGrowth 0.01800
grossMargins 0.75430
operatingMargins 0.20550
trailingEps 7.86000
forwardEps 12.79450

SYNGENE's current ratio being 1.38 shows it has more than enough assets to cover its short-term debts. The company's liquidity position is strong, with ample cash reserves available to meet its immediate financial obligations without strain.
SYNGENE's low earnings and revenue growth highlight potential profit shrinkage. This suggests that the company may struggle to maintain its financial performance, raising concerns about its future profitability.
SYNGENE's positive gross and operating margins indicate strong financial performance. These margins show that the company is profitable and efficient in its operations, with effective cost control contributing to its overall financial success.
Syngene International Limited's forward EPS being higher than its trailing EPS indicates that the company is expected to achieve greater profitability this financial year. This suggests improving earnings and a stronger financial position compared to the previous year's performance.

Price projections:

Price projections for SYNGENE
Price projections for SYNGENE

The stock price of SYNGENE has often been near the lower end of projections, indicating that it may not be meeting investor expectations. This trend could suggest challenges ahead for the company.

Recommendation changes over time:

Recommendations trend for SYNGENE
Recommendations trend for SYNGENE


Analysts have shown a buy bias for SYNGENE, marking it as a favorable investment option. This could inspire investors to see SYNGENE as a strong place to park their money, given the positive outlook and growth potential associated with the stock in recent evaluations.